Abstract
Dexmedetomidine is a sedating α-2 agonist that doesn't impair respiratory drive. In this multicenter study, investigators randomized 74 intensive care unit (ICU) patients with agitated delirium to receive either dexmedetomidine or placebo for ≤7 days. All patients were receiving mechanical ventilation and remained intubated only because lowering sedation levels to allow extubation would …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have